Sandoz Warns Fed. Circ. Enbrel Ruling Invites Patent Abuse
Sandoz Inc. has asked the Federal Circuit to reconsider upholding two patents covering Amgen's top-selling biologic Enbrel, warning that the concerning panel ruling cleared an "unprecedented" 31 years of exclusivity....To view the full article, register now.
Already a subscriber? Click here to view full article